[Report] Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer
Immunotherapy has clinical activity in certain virally associated cancers. However, the tumor antigens targeted in successful treatments remain poorly defined. We used a personalized immunogenomic approach to elucidate the global landscape of antitumor T cell responses in complete regression of human papillomavirus–associated metastatic cervical cancer after tumor-infiltrating adoptive T cell therapy. Remarkably, immunodominant T cell reactivities were directed against mutated neoantigens or a cancer germline antigen, rather than canonical viral antigens. T cells targeting viral tumor antigens did not display preferentia...
Source: ScienceNOW - April 13, 2017 Category: Science Authors: Sanja Stevanovi ć Source Type: news
Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer
Immunotherapy has clinical activity in certain virally associated cancers. However, the tumor antigens targeted in successful treatments remain poorly defined. We used a personalized immunogenomic approach to elucidate the global landscape of antitumor T cell responses in complete regression of human papillomavirus–associated metastatic cervical cancer after tumor-infiltrating adoptive T cell therapy. Remarkably, immunodominant T cell reactivities were directed against mutated neoantigens or a cancer germline antigen, rather than canonical viral antigens. T cells targeting viral tumor antigens did not display prefere...
Source: ScienceNOW - April 13, 2017 Category: Science Authors: Stevanovic, S., Pasetto, A., Helman, S. R., Gartner, J. J., Prickett, T. D., Howie, B., Robins, H. S., Robbins, P. F., Klebanoff, C. A., Rosenberg, S. A., Hinrichs, C. S. Tags: Immunology reports Source Type: news
The transcription factor MAFK induces EMT and malignant progression of triple-negative breast cancer cells through its target GPNMB
Triple-negative breast cancer (TNBC) is particularly aggressive and difficult to treat. For example, the transforming growth factor–β (TGF-β) pathway is implicated in TNBC progression and metastasis, but its opposing role in tumor suppression in healthy tissues and early-stage lesions makes it a challenging target. Therefore, additional molecular characterization of TNBC may lead to improved patient prognosis by informing the development and optimum use of targeted therapies. We found that musculoaponeurotic fibrosarcoma (MAF) oncogene family protein K (MAFK), a member of the small MAF family of transcripti...
Source: Signal Transduction Knowledge Environment - April 11, 2017 Category: Science Authors: Okita, Y., Kimura, M., Xie, R., Chen, C., Shen, L. T.-W., Kojima, Y., Suzuki, H., Muratani, M., Saitoh, M., Semba, K., Heldin, C.-H., Kato, M. Tags: STKE Research Articles Source Type: news
Survival Similar With Debulking by Laparotomy, Laparoscopy
Similar three - year survival rates for women with epithelial ovarian cancer undergoing debulking (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - April 10, 2017 Category: Cancer & Oncology Tags: Gynecology, Oncology, Surgery, Journal, Source Type: news
FDA Approves Niraparib for Recurrent Ovarian Cancer
The FDA announced the approval of niraparib, an oral PARP inhibitor, for the treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. (Source: CancerNetwork)
Source: CancerNetwork - March 28, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Gynecologic Cancers News Ovarian Cancer Source Type: news
FDA approves maintenance treatment for recurrent epithelial ovarian, fallopian tube or primary peritoneal cancers
The U.S. Food and Drug Administration today approved Zejula (niraparib) for the maintenance treatment (intended to delay cancer growth) of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, whose tumors have completely or partially shrunk (complete or partial response, respectively) in response to platinum-based chemotherapy. (Source: Food and Drug Administration)
Source: Food and Drug Administration - March 27, 2017 Category: American Health Source Type: news
Hitting cancer with high-intensity ultrasound, immunotherapy
In a new study, researchers have shown that combining high-intensity focused ultrasound with two immunotherapies (a PD-1 checkpoint inhibitor and TLR9 agonist) can produce excellent response rates in mouse models of epithelial cancer. They also found that, for the combination to be effective, immunotherapies must come first. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - March 23, 2017 Category: Science Source Type: news
Immunotherapy Motolimod Fails to Improve Survival in Ovarian Cancer
The addition of the immune therapy motolimod to pegylated liposomal doxorubicin failed to improve overall survival among women with recurrent epithelial ovarian carcinoma in a randomized phase II trial. (Source: CancerNetwork)
Source: CancerNetwork - March 15, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Gynecologic Cancers News Ovarian Cancer Conferences/SGO 2017 Source Type: news
Hormonal maintenance therapy may improve survival in women with rare serous carcinoma
For women with a rare subtype of chemo-resistant epithelial ovarian or peritoneum cancer, hormone maintenance therapy may significantly improve survival, according to a new study in theJournal of Clinical Oncology.Science Daily (Source: Society for Endocrinology)
Source: Society for Endocrinology - February 23, 2017 Category: Endocrinology Source Type: news
Hormonal maintenance therapy may improve survival in women with chemo-resistant rare ovarian or peritoneum cancer
For women with a rare subtype of epithelial ovarian or peritoneum cancer, known as low-grade serous carcinoma (LGSC), hormone maintenance therapy (HMT) may significantly improve survival, according to a new study. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - February 22, 2017 Category: Science Source Type: news
Hormonal maintenance therapy may improve survival in women with chemo-resistant rare ovarian or peri
(University of Texas M. D. Anderson Cancer Center) For women with a rare subtype of epithelial ovarian or peritoneum cancer, known as low-grade serous carcinoma (LGSC), hormone maintenance therapy (HMT) may significantly improve survival, according to a new study from researchers at The University of Texas MD Anderson Cancer Center. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 21, 2017 Category: Cancer & Oncology Source Type: news
PID and the Risk of Ovarian Cancer and Borderline Tumors PID and the Risk of Ovarian Cancer and Borderline Tumors
Is there a link between pelvic inflammatory disease and the risk of epithelial ovarian cancer or other ovarian tumors?American Journal of Epidemiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 15, 2017 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
Scientists discover how the cells in skin and organ linings maintain constant cell numbers
(University of Utah Health Sciences) Research published today in Nature from scientists at Huntsman Cancer Institute (HCI) at the University of Utah shows how epithelial cells naturally turn over, maintaining constant numbers between cell division and cell death. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 15, 2017 Category: Cancer & Oncology Source Type: news
Scientists discover how epithelial cells maintain constant cell numbers
(University of Utah Health Sciences) Research published today in Nature from scientists at Huntsman Cancer Institute (HCI) at the University of Utah shows how epithelial cells naturally turn over, maintaining constant numbers between cell division and cell death. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 15, 2017 Category: Global & Universal Source Type: news
